Biomea Fusion (BMEA) Q4 2025 earnings summary

Executive summary

• Advanced from preclinical validation to generating durable clinical data in type 2 diabetes with icovamenib, showing persistent 52-week clinical activity after a 12-week treatment course.

• Initiated two Phase II trials (COVALENT-211 and COVALENT-212) for icovamenib in type 2 diabetes, with 26-week primary endpoint data expected in Q4 2026.

• Launched Phase I trial for BMF-650 (GLP-131) in obesity, with initial 28-day weight reduction data anticipated in Q2 2026.

• Completed 52-week follow-up from Phase II COVALENT-112 (icovamenib in type 1 diabetes), with data expected in Q2 2026.

• Projected cash runway extends into Q1 2027.

Financial highlights

• Cash, cash equivalents, and restricted cash totaled $56.2 million as of December 31, 2025, down from $58.6 million at year-end 2024.

• Net loss attributable to common stockholders was $61.8 million for 2025, compared to $138.4 million in 2024.

• Research and development expenses were $62.0 million in 2025, down from $118.1 million in 2024, reflecting strategic realignment and reduced headcount.

• General and administrative expenses were $19.3 million in 2025, down from $26.0 million in 2024.

• Stock-based compensation totaled $9.5 million in 2025, down from $19.1 million in 2024.

Outlook and guidance

• Anticipates 26-week primary endpoint data from two Phase II icovamenib studies in type 2 diabetes in Q4 2026.

• Expects 52-week follow-up data from Phase II COVALENT-112 (type 1 diabetes) in Q2 2026.

• Initial 28-day weight reduction data from Phase I GLP-131 (BMF-650 in obesity) expected in Q2 2026.

• Cash runway projected into Q1 2027.